Neuroprotectant ApTOLL reduced death and disability in acute ischemic stroke patients
ApTOLL, a neuroprotective agent, has shown promising results in the APRIL 1b/2a trial and reduced death and disability when used alongside standard treatment in selected ischemic stroke patients. Rapid CTP helped with patient selection and mismatch determination.